Evaluation of the TRPM2 channel as a biomarker in breast cancer using public databases analysis

Boletín Médico Del Hospital Infantil de México (English Edition) Pub Date : 2016-11-01 DOI:10.1016/j.bmhime.2017.11.038

Adriana Sumoza-Toledo , Mario Iván Espinoza-Gabriel , Dvorak Montiel-Condado

{"title":"Evaluation of the TRPM2 channel as a biomarker in breast cancer using public databases analysis","authors":"Adriana Sumoza-Toledo , Mario Iván Espinoza-Gabriel , Dvorak Montiel-Condado","doi":"10.1016/j.bmhime.2017.11.038","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Breast cancer is one of the most common malignancies affecting women. Recent investigations have revealed a major role of ion channels in cancer. The transient receptor potential melastatin-2 (TRPM2) is a plasma membrane and lysosomal channel with important roles in cell migration and cell death in immune cells and tumor cells.</p></div><div><h3>Methods</h3><p>In this study, we investigated the prognostic value of TRPM2 channel in breast cancer, analyzing public databases compiled in Oncomine™ (Thermo Fisher, Ann Arbor, MI) and online Kaplan-Meier Plotter platforms.</p></div><div><h3>Results</h3><p>The results revealed that TRPM2 mRNA overexpression is significant <em>in situ</em> and invasive breast carcinoma compared to normal breast tissue. Furthermore, multi-gene validation using Oncomine™ showed that this channel is coexpressed with proteins related to cellular migration, transformation, and apoptosis. On the other hand, Kaplan-Meier analysis exhibited that low expression of TRPM2 could be used to predict poor outcome in ER- and HER2+ breast carcinoma patients.</p></div><div><h3>Conclusions</h3><p>TRPM2 is a promising biomarker for aggressiveness of breast cancer, and a potential target for the development of new therapies.</p></div>","PeriodicalId":100195,"journal":{"name":"Boletín Médico Del Hospital Infantil de México (English Edition)","volume":"73 6","pages":"Pages 397-404"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bmhime.2017.11.038","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Boletín Médico Del Hospital Infantil de México (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2444340917001121","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Breast cancer is one of the most common malignancies affecting women. Recent investigations have revealed a major role of ion channels in cancer. The transient receptor potential melastatin-2 (TRPM2) is a plasma membrane and lysosomal channel with important roles in cell migration and cell death in immune cells and tumor cells.

Methods

In this study, we investigated the prognostic value of TRPM2 channel in breast cancer, analyzing public databases compiled in Oncomine™ (Thermo Fisher, Ann Arbor, MI) and online Kaplan-Meier Plotter platforms.

Results

The results revealed that TRPM2 mRNA overexpression is significant in situ and invasive breast carcinoma compared to normal breast tissue. Furthermore, multi-gene validation using Oncomine™ showed that this channel is coexpressed with proteins related to cellular migration, transformation, and apoptosis. On the other hand, Kaplan-Meier analysis exhibited that low expression of TRPM2 could be used to predict poor outcome in ER- and HER2+ breast carcinoma patients.

Conclusions

TRPM2 is a promising biomarker for aggressiveness of breast cancer, and a potential target for the development of new therapies.

查看原文本刊更多论文

利用公共数据库分析评估TRPM2通道作为乳腺癌的生物标志物

乳腺癌是影响女性的最常见的恶性肿瘤之一。最近的研究揭示了离子通道在癌症中的重要作用。瞬时受体电位褪黑抑素-2 (TRPM2)是免疫细胞和肿瘤细胞的质膜和溶酶体通道，在细胞迁移和细胞死亡中起重要作用。方法在本研究中，我们通过分析Oncomine™(Thermo Fisher, Ann Arbor, MI)和在线Kaplan-Meier Plotter平台的公共数据库，研究TRPM2通道在乳腺癌中的预后价值。结果TRPM2 mRNA在原位乳腺癌和浸润性乳腺癌中均明显过表达。此外，使用Oncomine™进行的多基因验证表明，该通道与细胞迁移、转化和凋亡相关的蛋白共表达。另一方面，Kaplan-Meier分析显示，TRPM2低表达可用于预测ER-和HER2+乳腺癌患者预后不良。结论strpm2是一种很有前景的乳腺癌侵袭性生物标志物，是开发新疗法的潜在靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Boletín Médico Del Hospital Infantil de México (English Edition)

自引率

0.00%

发文量